A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marie Nguyen, MD
Celgene
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
164 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Universitair Ziekenhuis Brussel
Brussels, Belgium
- Jewish General Hospital
Montreal, Quebec, Canada
- Beijing Cancer Hospital - Beijing Institute for Cancer Research
Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
- Chinese Pla General Hospital / 307 Hospital
Beijing, China
- Bengbu Medical College - First Affiliated Hospital
Bengbu Shi, China
- First Hospital of Jilin University
Changchun, China
- Jilin Province Cancer Hospital
Changchun, China
- Central South University - Xiangya School of Medicine - Hunan Cancer Hospital
Changsha, China
- Central South University - Xiangya School of Medicine - Hunan Cancer Hospital
Changsha-shi, China
- Sichuan Cancer Hospital & Institute
Chengdu, China
- Sichuan University - West China Hospital
Chengdu, China
- Foshan First People'S Hospital
Foshan, China
- Cancer Center of Guangzhou Medical University
Guangzhou, China
- the First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
- Zhejiang Medical University - Zhejiang Cancer Hospital
Hangzhou, China
- Zhejiang University School of Medicine - the Second Affiliated Hospital
Hangzhou, China
- the First Affiliated Hospital of Harbin Medical University
Harbin, China
- Yunnan Cancer Hospital
Kunming, China
- Guangxi Tumour Institute and Hospital
Nanning, China
- Nantong Tumor Hospital
Nantong, China
- Fudan University Shanghai Cancer Center
Shanghai, China
- Shanghai Chest Hospital
Shanghai Shi, China
- Chongqing Cancer Hospital
Shapingbaqu, China
- Liaoning Cancer Hospital & Institute
Shenyang, China
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
- Zhongnan Hospital of Wuhan University
Wuhan, China
- the First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, China
- First Hospital of Xiamen
Xiamen, China
- Fujian Medical University - Fujian Provincial Cancer Hospital
Xidajie, China
- the Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
- the First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
- Zhengzhou University (zzu) - Henan Cancer Hospital
Zhengzhou, China
- the First Hospital of Xinjiang Medical University
Ürümqi, China
- Tampereen Yliopistollinen Sairaala
Tampere, Finland
- Turku University Hospital
Turku, Finland
- Centre Francois Baclesse
Caen, France
- Clinique Victor Hugo
Le Mans, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 May 2019
- Primary completion
- 26 Jun 2019
- Completion
- 26 Jun 2019
- Last update posted
- 15 Jul 2020
- Registered enrollment
- 1
- Registry id
- NCT03745222
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.